argenx SE (ARGX)
NASDAQ: ARGX · Real-Time Price · USD
1,033.15
-20.31 (-1.93%)
Sep 4, 2026, 4:00 PM EDT - Market closed
argenx SE Revenue
argenx SE had revenue of $1.54B in the quarter ending June 30, 2026, with 59.30% growth. This brings the company's revenue in the last twelve months to $5.33B, up 70.51% year-over-year. In the year 2025, argenx SE had annual revenue of $4.25B with 88.63% growth.
Revenue (ttm)
$5.33B
Revenue Growth
+70.51%
P/S Ratio
12.22
Revenue / Employee
$2,853,177
Employees
1,863
Market Cap
64.94B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.25B | 2.00B | 88.63% |
| Dec 31, 2024 | 2.25B | 983.45M | 77.52% |
| Dec 31, 2023 | 1.27B | 823.33M | 184.91% |
| Dec 31, 2022 | 445.27M | -94.15M | -17.45% |
| Dec 31, 2021 | 539.42M | 474.51M | 731.01% |
| Dec 31, 2020 | 64.91M | -29.11M | -30.96% |
| Dec 31, 2019 | 94.03M | 60.43M | 179.91% |
| Dec 31, 2018 | 33.59M | 27.09M | 416.32% |
| Dec 31, 2014 | 6.51M | -719.25K | -9.95% |
| Dec 31, 2013 | 7.23M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Regeneron Pharmaceuticals | 15.53B |
| Vertex Pharmaceuticals | 12.59B |
| BeOne Medicines AG | 6.13B |
| Incyte | 5.82B |
| Alnylam Pharmaceuticals | 4.80B |
| BioNTech SE | 3.03B |
| Royalty Pharma | 2.54B |
| Moderna | 2.23B |
ARGX News
- 3 days ago - BenchSci Announces Two-Year Enterprise Agreement with argenx to Advance AI-Driven Preclinical Drug Discovery - Business Wire
- 3 days ago - Argenx Has Delivered 18 Consecutive Quarters of Sales Growth -- but Is the Biotech Stock Still Underrated? - The Motley Fool
- 4 days ago - argenx to Present at Upcoming Investor Conferences - GlobeNewsWire
- 4 days ago - ARGX Maintained by Morgan Stanley -- Price Target Raised to $1250 - GuruFocus
- 5 days ago - Argenx price target raised to $1,250 from $1,230 at Morgan Stanley - TheFly
- 9 days ago - argenx Completes Acquisition of Forte Biosciences, Inc. - GlobeNewsWire
- 9 days ago - ARGX Upgraded by UBS -- Price Target Raised to $1400 - GuruFocus
- 9 days ago - ARGX Looks 29.0% Undervalued on GF Value⢠- GuruFocus